Post-Covid-19 Epidemic Era, Liquid Biopsy Industry Development Trend Analysis Report 2023
MARKET COMPETITIVE LANDSCAPE:
Major players in this market include Roche Diagnostics, Illumina, Guardant Health, Thermo Fisher Scientific, Exact Sciences Corp. , and etc.
---The combined market share of the Top 3 players in the global Liquid Biopsy market is about 52.32%.
REGION SHARE:
The report covers the market size information of major Regions/Countries around the world, including NA/United States, EU/Germany, APAC/China, LA/SA, MEA and etc.
---In the geographical distribution of Liquid Biopsy market in 2022, the North America has the largest market size and its market share is about 51.22%, followed by Europe and its market share is about 24.62%.
SEGMENT OVERVIEW:
This report conducts segment analysis on type and application level. Type segment includes Instruments , Kits, etc. Application segment includes Screening/Early Detection, Diagnostics, etc.
---Circulating Tumor DNA (ctDNA) contributes approximately 39.59% share to the market in 2022.
---Colorectal Cancer contributes approximately 21.16% share to the market in 2022.
The cumulative impact of COVID-19, Russia-Ukraine conflict, and high inflation is expected to have a significant long-term impact on the global Liquid Biopsy markets. Ongoing research considers changes in consumer behavior, supply chain disruptions, and government intervention caused by the pandemic. Likewise, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine conflict and its potential impact on the supply-demand balance, pressure on pricing variables, and import, export, and trade. In addition, the report discusses the impact of high inflation on the global economy and details fiscal policies to measure and reduce its impact on demand, supply, cash flows, and currency exchange.
Market Statistics:
Reports provide market sizes and forecasts for multiple major currencies (USD, EUR, JPY, GBP, CNY, etc.); multi-currency support helps organizational leaders make informed decisions. This report takes 2018-2021 as the historical year, 2022 as the base year, 2023 as the semi-forecast year, and 2024-2029 as the full forecast year.
Market Share Analysis:
Market share analysis provides deep insights into the current status of vendors in a particular market space. By comparing suppliers” contributions to total revenue, customer base, and other key metrics, we can give companies a better understanding of their performance and the challenges they face as they compete for market share. The analysis also sheds light on the competitiveness of any given sector in terms of accumulation, diversification of strengths, and consolidation characteristics during the base year studied.
The report provides insights on the following metrics:
Market Penetration: Provides comprehensive information on the market offered by key players
Market Diversification: Provides detailed information on new product launches, greenfield regions, recent developments and investments
Market Trends: A Big Picture of the Cumulative Impact of COVID-19, Russia-Ukraine Conflict, and High Inflation
Competitive assessment and intelligence: Provides an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape and manufacturing capabilities of leading players
Product Development & Innovation: Provides intelligent insights into future technologies, R&D activities, and breakthrough product developments
Market Segmentation: Segment by Type, Application, and Region to provide detailed insights into market information.
Increasing Adoption: Liquid biopsies were gaining significant adoption in clinical practice and research settings. The non-invasive nature of liquid biopsies made them attractive for patients, and they were being used to complement or replace traditional tissue biopsies in certain cases.
Cancer Applications: Liquid biopsies were primarily being used for cancer detection, monitoring, and treatment selection. They allowed for the detection of genetic alterations, such as mutations, amplifications, and fusions, in circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs). This information could guide treatment decisions and help in monitoring treatment response and the development of resistance.
Research and Development: There was active research and development in the liquid biopsy field to expand its applications beyond cancer. Researchers were exploring the potential of liquid biopsies in areas such as prenatal testing, infectious diseases, neurological disorders, and transplant monitoring. These efforts aimed to enhance the clinical utility of liquid biopsies in various diseases and conditions.
Technological Advancements: The liquid biopsy market was witnessing continuous technological advancements. New techniques and platforms were being developed to improve the sensitivity, specificity, and cost-effectiveness of liquid biopsy tests. This included the development of next-generation sequencing (NGS) technologies, digital PCR, and other innovative approaches for detecting and analyzing ctDNA or CTCs.
Regulatory Landscape: The regulatory landscape for liquid biopsies was evolving. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), were actively working on establishing guidelines and approving specific liquid biopsy tests for clinical use. These regulations were important for ensuring the accuracy, reliability, and clinical validity of liquid biopsy assays.
Highlights-Regions
North America
United States
Canada
China
Asia Pacific (Excluding China)
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Nordic
Latin America
Brazil
Argentina
Mexico
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Player list
Roche Diagnostics
Illumina
Guardant Health
Thermo Fisher Scientific
Exact Sciences Corp.
Qiagen
Bio-Rad Laboratories
Sysmex Inostics
Mdxhealth
Menarini-Silicon Biosystems
Personal Genome Diagnostics, Inc.
Biocept
Types list
Instruments
Kits
Services
Application list
Screening/Early Detection
Diagnostics
Therapy monitoring
Recurrence monitoring
Contact US Anytime
- Tel: +86 195 30455980
- Email: reports@arstaresearch.com
Find More
Post-Covid-19 Epidemic Era, Liquid Biopsy Industry Development Trend Analysis Report 2023
Get a FREE sample
Have Requests? Need Customization? Our Research Team Will Help to Maximize Your "Interest Scope and Content Customization" into Our Analysis Report.
Custom Research